1 min read
Add as a preferred source on Google

Bausch + Lomb's BL1332 Misses Primary Goal in Phase 2 Eye Pain Trial

At 24 hours, the topical drug for pain after eye surgery showed no statistically significant improvement over vehicle, an inactive comparison formulation.

Amber dropper bottle standing on a pale laboratory bench in morning light. / TokenPost.ai
Amber dropper bottle standing on a pale laboratory bench in morning light. / TokenPost.ai

Bausch + Lomb Corporation's experimental BL1332, a topical TRPV1 antagonist for pain after eye surgery, failed to meet the primary endpoint of a Phase 2 clinical trial.

At 24 hours, BL1332 did not show a statistically significant improvement compared with vehicle. A vehicle is an inactive formulation used as the comparison in a trial.

BL1332 is being developed for post-surgical ocular pain. Bausch + Lomb trades under the ticker BLCO.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…